U87 CART in Treatment of Advanced Solid Tumor
Clinical Study to Evaluate the Safety and Efficacy of U87 CART in Treatment of Advanced Solid Tumor
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Estimated)
Enrollment
Phase
Phase
- Phase 1
Contacts and Locations
Study Contact
Study Contact
- Name: Maoquan Li, doctor
- Phone Number: 021-66300114*3506
- Email: cjr.limaoquan@vip.163.com
Study Contact Backup
- Name: Shilong Han, doctor
- Phone Number: 021-66303247
Study Locations
-
-
-
Shanghai, China
- Recruiting
- China Shanghai 10th People's Hospital
-
Contact:
- Li mao quan, doctor
- Phone Number: 3506 021-66300114
- Email: cjr.limaoquan@vip.163.com
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Voluntary informed consent is given;
- Age 18 to 75;
- Patients with pathologically confirmed advanced solid tumor who have failed first-line therapy; or patients who are intolerant to first-line standard therapy and voluntarily give up standard therapy;
- Immunohistochemical (IHC) staining of tumor tissue samples from patients was positive for U87 specific antigen (≥ 2 +, and the expression rate was ≥ 20%);
- Expected survival ≥12 weeks;
- Measurable tumor lesions according to RECIST 1.1;
- ECOG performance score 0-1;
- Sufficient venous access for mononuclear cell collection;
- HBc Ab positive, HBsAg negative can be included in the group when the PCR detection of HBV DNA is negative;
- Patients should maintain adequate organ function;
- Dyspnea (CTCAE v5.0) ≤ Grade 1; Blood oxygen saturation>91% without oxygen inhalation;
- Pregnancy test was negative in women of childbearing age; Both male and female subjects should agree to use effective contraceptives during the treatment period and within the following year;
Exclusion Criteria:
- Pregnant or lactating women;
- Uncontrolled active infections;
- Active Syphilis, HIV, hepatitis B or hepatitis C infection;
- Congenital immunodeficiency;
- Have serious allergic reaction to any drug to be used in this study;
- Other incurable malignant tumors in the past three years;
- History or presence of clinically relevant CNS pathology such as epilepsy, Cerebrovascular ischemia/hemorrhage, dementia, cerebellar disease, or any CNS-related autoimmune disease;
- Have undergone cardiac angioplasty or stent implantation within 12 months, or have a history of myocardial infarction, unstable angina or other clinically significant heart diseases;
- Subjects requiring anticoagulation or long-term antiplatelet therapy;
- Subjects who have undergone major surgery or significant trauma within four weeks before enrolled in the study.
- Other situations that the investigator thinks are not suitable for participating in this study.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: U87 CAR-T cells
The Patients are enrolled into 2 dose level cohorts in sequence
|
Subjects will be pretreated with cyclophosphamide 250~500 mg/m2( body surface area) for 3 days prior to Intravenous injection of U87, followed by intraartery of U87 14 days later with intravenous IL-2.
Researchers can perform intratumoral injection based on their judgment.This study will explore two dose of dose 1 (DL-1): 1×106 (±20%) to dose 2 (DL-2): 1×107 (±20%),each group was enrolled in 3~6 patients.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Incidence of Adverse events after U87 CAR-T cells infusion [Safety and Tolerability]
Time Frame: 28 days post administration of CAR-T-cells
|
Therapy-related adverse events were recorded and assessed according to the National Cancer Institute's Common Terminology Criteria for Adverse Events (CTCAE, Version 5.0) Dose-limiting toxicity after U87 CAR-T cells infusion.
|
28 days post administration of CAR-T-cells
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Pharmacokinetics of U87 CAR-T cells
Time Frame: 2 years post CAR T cell infusion
|
Peak value of eripheral blood (Cmax)
|
2 years post CAR T cell infusion
|
|
Pharmacokinetics of U87 CAR-T cells
Time Frame: 2 years post CAR T cell infusion
|
Area under the eripheral blood concentration versus time curve (AUC)
|
2 years post CAR T cell infusion
|
|
Pharmacokinetics of U87 CAR-T cells
Time Frame: 2 years post CAR T cell infusion
|
Time of peak value
|
2 years post CAR T cell infusion
|
|
Pharmacodynamics of U87 CAR-T cells
Time Frame: 2 years post CAR T cell infusion
|
Concentration levels of CAR-T-related serum cytokines such as IL-6, IFN γ, IL-2, TNFα, ferritin and CRP at each time point
|
2 years post CAR T cell infusion
|
|
Disease control rate (DCR) of U87 CAR-T cells treatment in advanced solid tumor. [Effectiveness]
Time Frame: 2 years post CAR T cell infusion
|
Disease control rate: including CR, PR and SD(Assessed based on RECIST 1.1 criteria)
|
2 years post CAR T cell infusion
|
|
Objective response rate (ORR) of U87 CAR-T cells treatment in advanced solid tumor. [Effectiveness]
Time Frame: 2 years post CAR T cell infusion
|
Objective response rate includes:CR、PR(Assessed based on RECIST1.1 criteria)
|
2 years post CAR T cell infusion
|
|
Duration of Response (DOR) of U87 CAR-T cells treatment in advanced solid tumot[Effectiveness]
Time Frame: 2 years post CAR T cell infusion
|
DOR will be assessed from the first assessment of CR/PR/SD to the first assessment of recurrence or progression of the disease or death from any cause
|
2 years post CAR T cell infusion
|
|
Progress-free survival(PFS) of U87 CAR-T cells treatment in advanced solid tumor[Effectiveness]
Time Frame: 2 years post CAR T cell infusion
|
PFS will be assessed from the first U87 CAR-T cells infusion to death from any cause or the first assessment of progression(Assessed based on RECIST1.1 ) criteria)
|
2 years post CAR T cell infusion
|
|
Overall survival(OS) of U87 CAR-T cells treatment in advanced solid tumor [Effectiveness]
Time Frame: 2 years post CAR T cell infusion
|
OS will be assessed from the first U87 CAR-T cells infusion to death from any cause (Assessed based on RECIST 1.1 criteria)
|
2 years post CAR T cell infusion
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- U87-3
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.